Company: PMVP
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001140361-25-015610
Chunk: 55

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 55
---
 unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer.

33

TABLE OF CONTENTS PROPOSAL NO. 1: ELECTION OF CLASS II DIRECTORS Number of Directors; Board Structure Our board of directors currently consists of seven members. Our directors are divided into three classes serving staggered three year terms. Upon expiration of the term of a class of directors, directors in that class will be eligible to be elected for a new three year term at the annual meeting of stockholders in the year in which their term expires. The terms of the Class II directors, Arnold Levine, Ph.D. and Charles M. Baum, M.D., Ph.D., expire at the Annual Meeting. The Class III directors will serve until our annual meeting of stockholders in 2026. The Class I directors will serve until our annual meeting of stockholders in 2027. Nominees Our nominating and corporate governance committee has recommended, and our board of directors has approved, Arnold Levine, Ph.D. and Charles M. Baum, M.D., Ph.D. as nominees for election as Class II directors at the Annual Meeting. If elected, each of Arnold Levine, Ph.D. and Charles M. Baum, M.D., Ph.D. will serve as a Class II director until the 2028 annual meeting of stockholders and until their respective successor is elected and qualified or until their earlier death, resignation or removal. For more information concerning the nominees, please see the section titled “ Board of Directors and Corporate Governance.” Arnold Levine, Ph.D. and Charles M. Baum, M.D., Ph.D. have agreed to serve as directors if elected, and management has no reason to believe that they will be unavailable to serve. In the event a nominee is unable or declines to serve as a director at the time of the Annual Meeting, proxies will be voted for any nominee designated by the present board of directors to fill the vacancy. Vote Required Each director is elected by a plurality of the voting power of the shares present in person (including virtually) or represented by proxy at the meeting and entitled to vote on the election of directors. Because the outcome of this proposal will be determined by a plurality vote, any shares not voted FOR a particular nominee, whether as a result of choosing to WITHHOLD authority to vote or a broker non-vote, will